Multiple myeloma is a deadly form of blood cancer, characterized by excessive numbers of abnormal plasma cells in the bone marrow and the overproduction of abnormal immunoglobulins.
Recently, CuraGen Corporation and TopoTarget A/S initiated the patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade® (bortezomib) for the treatment of relapsed, refractory multiple myeloma (MM).
The goal of the Phase Ib portion of this trial is to establish the maximum tolerated dose (MTD) of PXD101 in combination with Velcade® in up to 30 patients who have failed at least two prior lines of therapy for multiple myeloma.
Following determination of the MTD, the study will enter Phase II and enroll up to 15 additional patients with relapsed, refractory multiple myeloma who have failed at least one prior therapy.
The Phase II portion of the study will further evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PXD101 in combination with Velcade®. Patients will be enrolled at multiple sites in the United States.
Read Curagen’s press release.
Photo Credit: Millennium Products
.jpg)
» CuraGen and TopoTarget Commenced Phase I/II Trial of PXD101 for Hepatocellular Cancer (Liver Cancer) from ThePharmVoice
CuraGen Corporation and TopoTarget A/S commenced the patient dosing of PXD101 (a small molecule histone deacetylase (HDAC) inhibitor) in a Phase I/II clinical trial evaluating the safety and potential efficacy of the product for the treatment of inoper... [Read More]
Tracked on: July 17, 2006 8:56 PM | Permalink to Trackback